FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891767331> ?p ?o ?g. }

• W2891767331 abstract "Thromboembolic events are associated with high mortality and morbidity indexes. In this context, warfarin is the most widely prescribed oral anticoagulant agent for preventing and treating these events. This medication has a narrow therapeutic range and, consequently, patients usually have difficulty in achieving and maintaining stable target therapeutics. Some studies on the literature about oral anticoagulant management showed that pharmacists could improve the efficiency of anticoagulant therapy. However, the majority of these studies included general patients retrospectively. The aim of this study was to prospectively evaluate a pharmacist’s warfarin management in patients with poor quality of anticoagulation therapy (Time in the Therapeutic Range- TTR<50%). We included 268 patients with atrial fibrillation and without stable dose of warfarin (TTR <50%, based on the last three values of International Normalized Ratio-INR). We followed them up for 12 weeks, INR values were evaluated and, when necessary, the dose adjustments were performed. During the first four visits, patient’s INR was measured every 7 days. Then, if INR was within the target therapeutic range (INR: 2-3), the patient was asked to return in 30 days. However, if INR was out the therapeutic target, the patient was asked to return in 7 days. Adherence evaluation was measured through questionnaires and by counting the pills taken. Comparison between basal TTR (which was calculated based on the three last INR values before prospective phase) and TTR of 4 weeks (calculated by considering the INR tests from visit 0 to visit 4, in the prospective phase of the study) and basal TTR and TTR of 12 weeks (calculated based on the INR tests from visit 0 to visit 12, in the prospective phase of the study) revealed significant statistical differences (0.144±0.010 vs 0.382±0.016; and 0.144±0.010 vs 0.543±0.014, p<0.001; respectively). We also observed that the mean TTR of 1 year before (retrospective phase) was lower than TTR value after 12 weeks of pharmacist-driven treatment (prospective phase) (0.320±0.015; 0.540±0.015, p<0.001). In conclusion, pharmaceutical care was able to improve TTR values in patients with atrial fibrillation and poor quality of anticoagulation with warfarin." @default.
• W2891767331 created "2018-09-27" @default.
• W2891767331 creator A5003994616 @default.
• W2891767331 creator A5006939502 @default.
• W2891767331 creator A5011211243 @default.
• W2891767331 creator A5021394653 @default.
• W2891767331 creator A5027096752 @default.
• W2891767331 creator A5032544285 @default.
• W2891767331 creator A5048178623 @default.
• W2891767331 creator A5069859243 @default.
• W2891767331 creator A5071884885 @default.
• W2891767331 creator A5080556061 @default.
• W2891767331 creator A5087881782 @default.
• W2891767331 date "2018-09-21" @default.
• W2891767331 modified "2023-10-17" @default.
• W2891767331 title "Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin" @default.
• W2891767331 cites W1586488555 @default.
• W2891767331 cites W1849629338 @default.
• W2891767331 cites W1863714865 @default.
• W2891767331 cites W1998354077 @default.
• W2891767331 cites W1999468381 @default.
• W2891767331 cites W2020214475 @default.
• W2891767331 cites W2022396772 @default.
• W2891767331 cites W2024301885 @default.
• W2891767331 cites W2047097854 @default.
• W2891767331 cites W2051188170 @default.
• W2891767331 cites W2055771484 @default.
• W2891767331 cites W2056809554 @default.
• W2891767331 cites W2065759880 @default.
• W2891767331 cites W2068476516 @default.
• W2891767331 cites W2069436156 @default.
• W2891767331 cites W2092492353 @default.
• W2891767331 cites W2093274439 @default.
• W2891767331 cites W2103053426 @default.
• W2891767331 cites W2114775432 @default.
• W2891767331 cites W2123257771 @default.
• W2891767331 cites W2134024367 @default.
• W2891767331 cites W2147018083 @default.
• W2891767331 cites W2164861810 @default.
• W2891767331 cites W2282258694 @default.
• W2891767331 cites W2403096672 @default.
• W2891767331 cites W2479970480 @default.
• W2891767331 cites W2509795914 @default.
• W2891767331 cites W2548706052 @default.
• W2891767331 cites W2554721352 @default.
• W2891767331 cites W2557323610 @default.
• W2891767331 cites W2612014406 @default.
• W2891767331 cites W2754055777 @default.
• W2891767331 cites W2766027049 @default.
• W2891767331 cites W2790204922 @default.
• W2891767331 cites W2790965983 @default.
• W2891767331 cites W2793257615 @default.
• W2891767331 cites W2799729742 @default.
• W2891767331 cites W2799855806 @default.
• W2891767331 cites W2802651128 @default.
• W2891767331 cites W3004050106 @default.
• W2891767331 cites W4250091292 @default.
• W2891767331 cites W907662363 @default.
• W2891767331 doi "https://doi.org/10.3389/fphar.2018.01052" @default.
• W2891767331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6160801" @default.
• W2891767331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30298004" @default.
• W2891767331 hasPublicationYear "2018" @default.
• W2891767331 type Work @default.
• W2891767331 sameAs 2891767331 @default.
• W2891767331 citedByCount "16" @default.
• W2891767331 countsByYear W28917673312019 @default.
• W2891767331 countsByYear W28917673312020 @default.
• W2891767331 countsByYear W28917673312021 @default.
• W2891767331 countsByYear W28917673312022 @default.
• W2891767331 countsByYear W28917673312023 @default.
• W2891767331 crossrefType "journal-article" @default.
• W2891767331 hasAuthorship W2891767331A5003994616 @default.
• W2891767331 hasAuthorship W2891767331A5006939502 @default.
• W2891767331 hasAuthorship W2891767331A5011211243 @default.
• W2891767331 hasAuthorship W2891767331A5021394653 @default.
• W2891767331 hasAuthorship W2891767331A5027096752 @default.
• W2891767331 hasAuthorship W2891767331A5032544285 @default.
• W2891767331 hasAuthorship W2891767331A5048178623 @default.
• W2891767331 hasAuthorship W2891767331A5069859243 @default.
• W2891767331 hasAuthorship W2891767331A5071884885 @default.
• W2891767331 hasAuthorship W2891767331A5080556061 @default.
• W2891767331 hasAuthorship W2891767331A5087881782 @default.
• W2891767331 hasBestOaLocation W28917673311 @default.
• W2891767331 hasConcept C104863432 @default.
• W2891767331 hasConcept C126322002 @default.
• W2891767331 hasConcept C151730666 @default.
• W2891767331 hasConcept C177713679 @default.
• W2891767331 hasConcept C188816634 @default.
• W2891767331 hasConcept C194828623 @default.
• W2891767331 hasConcept C19831878 @default.
• W2891767331 hasConcept C2776301958 @default.
• W2891767331 hasConcept C2778205648 @default.
• W2891767331 hasConcept C2779161974 @default.
• W2891767331 hasConcept C2779343474 @default.
• W2891767331 hasConcept C2779457091 @default.
• W2891767331 hasConcept C2780035454 @default.
• W2891767331 hasConcept C2992750412 @default.
• W2891767331 hasConcept C512399662 @default.
• W2891767331 hasConcept C71924100 @default.
• W2891767331 hasConcept C86803240 @default.

• next